Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

David Digomann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2139-9183; OpenAlex author ID A5026280128. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 9

  1. Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. Co-author DOI 10.1172/jci.insight.194290↗
  2. Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-026-19628-8↗
  3. ASO Visual Abstract: Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Sur… Co-author DOI 10.1245/s10434-026-19708-9↗
  4. The Value of Blood T Cell Frequencies for Risk Prediction of Postoperative Complications in Pancreatic Cancer Surgery. Co-author DOI 10.1097/as9.0000000000000545↗
  5. Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. Co-author DOI 10.1038/s41698-023-00459-9↗
  6. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0258↗
  7. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Co-author DOI 10.3390/cancers15082326↗
  8. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. Co-author DOI 10.1172/jci.insight.152761↗
  9. LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers13061297↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adrian M. Seifert · 9 shared papers, 2021–2026 · strength 1.70
  2. Lena Seifert · 9 shared papers, 2021–2026 · strength 1.70
  3. Jürgen Weitz · 9 shared papers, 2021–2026 · strength 1.70
  4. Max Heiduk · 7 shared papers, 2021–2026 · strength 1.20
  5. Loreen Natusch · 4 shared papers, 2025–2026 · strength 0.96
  6. Sarah Cronjaeger · 3 shared papers, 2026 · strength 0.74
  7. Sebastian Hempel · 3 shared papers, 2025–2026 · strength 0.72
  8. Florian Oehme · 3 shared papers, 2025–2026 · strength 0.72
  9. Michael B. Ghadimi · 3 shared papers, 2023–2026 · strength 0.66
  10. Marius Distler · 3 shared papers, 2023–2025 · strength 0.55
  11. Ioana Plesca · 3 shared papers, 2021–2023 · strength 0.41
  12. Marc Schmitz · 3 shared papers, 2021–2023 · strength 0.41
  13. Christoph Kahlert · 2 shared papers, 2022–2023 · strength 0.29
  14. Franziska Baenke · 1 shared paper, 2026 · strength 0.24
  15. Daniel E. Stange · 1 shared paper, 2026 · strength 0.24
  16. Diane M. Simeone · 1 shared paper, 2026 · strength 0.24
  17. Jochen Gaedcke · 1 shared paper, 2023 · strength 0.16
  18. Luise Rupp · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.